May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?
Potenza
Leonardo
L
Luppi
Mario
M
Riva
Giovanni
G
Ottaviani
Emanuela
E
Zucchini
Patrizia
P
Morselli
Monica
M
Volzone
Francesco
F
Forghieri
Fabio
F
Martinelli
Giovanni
G
Torelli
Giuseppe
G
D000208:Acute Disease; D000328:Adult; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics*; D006801:Humans; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D007958:Leukocyte Count; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D017354:Point Mutation; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D000075142:RUNX1 Translocation Partner 1 Protein; D012008:Recurrence; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein; D019009:Proto-Oncogene Proteins c-kit